Do you consider tumor mutation burden as a possible biomarker for response to immune checkpoint therapy in the second line setting for cervical cancer?  

According to NCCN guidelines, pembrolizumab could be used as a second line therapy for tumors that are PDL1 positive, can be categorized as MSI-high (high microsatellite instability), or are deficiency in mismatch repair (Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to ...